Pfizer may present new growth hormone in 2022

The EMA has accepted Pfizer's and Opko's application to get a new growth hormone approved, which may compete with Novo Nordisk's and Ascendis' growth hormons.

Photo: Don Emmert/AFP/Ritzau Scanpix

The European Medicines Agency (EMA) has approved a Pfizer and Opko application concerning their joint growth hormone somatrogon.

Somatrogon is a once-weekly growth hormone aimed at treating people with growth hormone deficiency (GHD). As such, the therapy competes with new drugs in the same area produced by Novo Nordisk and Ascendis.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs